17 articles
GSK shares tumbled after third-quarter results showed vaccine sales dipping despite overall revenue growth, sparking investor concern over patent expiries. CEO Luke Miels outlined cost-saving measures
GSK exceeded Q3 sales and profit expectations driven by strong demand for new medicines, maintaining annual targets while boosting R&D investment ahead of patent expiries.
GSK plans to invest over $800 million to expand its Pennsylvania site into a biopharmaceutical hub, creating 300 new jobs by 2027. The facility will support clinical and commercial production of biolo
GSK plans to close its Dresden vaccine factory by summer 2027, risking 641 jobs as it consolidates production in Canada due to declining demand for traditional flu vaccines. The company also advances
GSK plans a £400m Cambridge R&D centre, closing its Stevenage facility. This strategic shift supports cost-cutting targets and drug pipeline acceleration despite near-term patent expiries.
GSK plans to cut over 1,000 jobs and close its Stevenage R&D site to fund a £400m investment in Cambridge, accelerating drug development in areas like oncology and vaccines.
Energy stocks rose on higher oil prices amid Middle East tensions, while GSK halted a late-stage drug trial. Meanwhile, Andy Burnham is set to become Britain's next prime minister.
GSK terminated its neuroscience collaboration with Alector after clinical failures of two antibody drugs for dementia and Alzheimer's. The move follows late-stage setbacks and led to significant workf
GSK acquired US cancer firm Nuvalent for $10.6bn in its largest deal since 2014. The purchase adds two late-stage lung cancer drugs to GSK's pipeline, pending FDA approval later this year.
US stock futures climbed as chip stocks extended gains and Middle East hostilities eased, causing oil prices to fall over 2%. GSK also agreed to acquire cancer drug developer Nuvalent for $10.6 billio
GSK announced plans to acquire Nuvalent for $10.6 billion, aiming to expand its small-molecule kinase inhibitor portfolio for treatment-resistant cancers under new CEO Luke Miels.
British drugmaker GSK agreed to acquire U.S. cancer developer Nuvalent for $10.6 billion to expand its lung cancer portfolio. The all-cash deal values Nuvalent at $124 per share and is expected to con
UK pharmaceutical group GSK is in talks to acquire cancer biotech Nuvalent for over $9 billion, aiming to expand its product pipeline. The potential deal reflects a broader biopharma M&A frenzy projec
AstraZeneca announced a £300m investment reversal in the UK, unfreezing paused projects in Cambridge and Macclesfield following a UK-US drug pricing deal. The announcement coincided with strong quarte
UK shares declined as traders digested mixed corporate earnings, with pharmaceutical giants AstraZeneca and GSK falling despite strong profit forecasts amidst geopolitical tensions.
Samsung Biologics completed a $280M acquisition of a GSK manufacturing facility in Maryland, marking the company's first manufacturing presence in the United States.
GSK plans to acquire Rapt Therapeutics for $2.2 billion while Vioneo relocates a project to China; concurrently, a US snowstorm highlights the essential role of chemical remedies in public safety.
ChemBrief